Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2018 Jun 15;17(9):1859–1870. doi: 10.1158/1535-7163.MCT-17-1176

Figure 4. Effects of bromocriptine on AR stability and ubiquitination.

Figure 4

(A) Upper panel: Western blot analysis of AR protein expression in C4-2 cells treated with 20 μM bromocriptine for varying times; Middle panel: Cells were pre-incubated with sulpiride (1 μM) for 1 h prior to bromocriptine treatment; Lower panel: Western blot analysis of AR protein expression in C4-2 cells treated with 20 μM bromocriptine for short term. (B) Upper paenel: Western blot analysis of AR expression in C4-2 cells pre-treated with CHX (50 μg/ml; 2 h) followed by treatment with DMSO or bromocriptine (20 μM) for the indicated times, or pre-treated with CHX for 1 h, followed by sulpiride for 1h and bromocriptine for the indicated times. Lower panel: T1/2 of AR proteins was calculated using SigmaPlot 13.0. (C) Left: Western blot analysis of protein expression of AR and Hsp90 in Hsp90 immunoprecipitates from C4-2 cells treated with DMSO (6 h), bromocriptine (20 μM, 6 h) or sulpiride (1 μM, 1 h) followed by bromocriptine (20 μM, 6 h). Right: Western blot analysis of expression of AR and ubiquitin in AR immunoprecipitates from C4-2 cells treated with DMSO (6 h), bromocriptine (20 μM, 6 h) or sulpiride (1 μM, 1 h) followed by bromocriptine (20 μM, 6 h).